Silvercrest Asset Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Silvercrest Asset Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-11,560	Closed	-$147K	–	596
2017 Q3	$147K	Hold	11,560	–	–	﹤0.01%	542
2017 Q2	$137K	Hold	11,560	–	–	﹤0.01%	526
2017 Q1	$171K	Hold	11,560	–	–	﹤0.01%	558
2016 Q4	$187K	Sell	11,560 -1,000	-8%	-$18.1K	﹤0.01%	560
2016 Q3	$228K	Sell	12,560 -3,000	-19%	-$58.6K	﹤0.01%	501
2016 Q2	$256K	Sell	15,560 -1,000	-6%	-$16.2K	﹤0.01%	492
2016 Q1	$274K	Hold	16,560	–	–	﹤0.01%	477
2015 Q4	$359K	Hold	16,560	–	–	0.01%	461
2015 Q3	$328K	Sell	16,560 -2,000	-11%	-$63.2K	0.01%	410
2015 Q2	$645K	Hold	18,560	–	–	0.01%	376
2015 Q1	$482K	Sell	18,560 -7,600	-29%	-$139K	0.01%	378
2014 Q4	$337K	Buy	+26,160	New	+$327K	﹤0.01%	393

Other funds holding HZNP

SCM

Scopia Capital Management New York $112M AUM 48.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

BGIM

Brandywine Global Investment Management Philadelphia, Pennsylvania $14.9B AUM 20.41% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Silvercrest Asset Management's HZNP Position: Q4 2017 in Review

Silvercrest Asset Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2017, closing a stake of 11,560 shares — an estimated $147K sold.

Silvercrest Asset Management first reported a position in HZNP in Q4 2014 and held it in 12 quarters. The position peaked at $645K in Q2 2015. 183 funds tracked by Wall St. Rank hold HZNP as of Q4 2017.

Silvercrest Asset Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2017 after selling out during the quarter.
Silvercrest Asset Management sold 11,560 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2017, an estimated $147K.
Silvercrest Asset Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2014 and held it in 12 quarters.
Silvercrest Asset Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $645K in Q2 2015.
183 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2017.

Based on Silvercrest Asset Management's 13F filing for Q4 2017, filed 14 Feb 2018.